Format

Send to

Choose Destination
Cell Tissue Res. 2018 Jul;373(1):39-50. doi: 10.1007/s00441-017-2759-9. Epub 2018 Jan 8.

The LRRK2 signalling system.

Author information

1
School of Pharmacy, University of Reading, Whiteknights, Reading, RG6 6AP, UK.
2
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
3
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Building. 35, 35 Convent Drive, Bethesda, MD, 20892, USA.
4
School of Pharmacy, University of Reading, Whiteknights, Reading, RG6 6AP, UK. p.a.lewis@reading.ac.uk.
5
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK. p.a.lewis@reading.ac.uk.

Abstract

The LRRK2 gene is a major contributor to genetic risk for Parkinson's disease and understanding the biology of the leucine-rich repeat kinase 2 (LRRK2, the protein product of this gene) is an important goal in Parkinson's research. LRRK2 is a multi-domain, multi-activity enzyme and has been implicated in a wide range of signalling events within the cell. Because of the complexities of the signal transduction pathways in which LRRK2 is involved, it has been challenging to generate a clear idea as to how mutations and disease associated variants in this gene are altered in disease. Understanding the events in which LRRK2 is involved at a systems level is therefore critical to fully understand the biology and pathobiology of this protein and is the subject of this review.

KEYWORDS:

Kinase; LRRK2; Parkinson’s disease; ROCO protein; Signal transduction

PMID:
29308544
PMCID:
PMC6015615
DOI:
10.1007/s00441-017-2759-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center